Pantoprazole
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Pantoprazole |
| DrugBank ID | DB00213 |
| Brand Names (EU) | Somac Control |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.87% |
Approved Indication (EMA)
Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | peptic esophagitis | 99.87% | DL |
| 2 | multiple endocrine neoplasia | 99.81% | DL |
| 3 | active peptic ulcer disease | 99.69% | DL |
| 4 | peptic ulcer perforation | 99.63% | DL |
| 5 | gastrojejunal ulcer | 99.63% | DL |
| 6 | duodenogastric reflux | 99.27% | DL |
| 7 | esophagitis (disease) | 99.24% | DL |
| 8 | duodenal obstruction | 99.21% | DL |
| 9 | duodenal ulcer (disease) | 99.18% | DL |
| 10 | acne (disease) | 98.35% | DL |
| 11 | gastric ulcer (disease) | 98.05% | DL |
| 12 | Zollinger-Ellison syndrome | 97.92% | DL |
| 13 | Smouldering systemic mastocytosis | 97.38% | DL |
| 14 | gastrin secretion abnormality | 96.77% | DL |
| 15 | lymphoadenopathic mastocytosis with eosinophilia | 96.60% | DL |
| 16 | gastroduodenitis | 96.47% | DL |
| 17 | peptic ulcer disease | 93.12% | DL |
| 18 | systemic mastocytosis | 92.63% | DL |
| 19 | abnormality of glucagon secretion | 84.85% | DL |
| 20 | leather-bottle stomach | 84.77% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.